Erratum: An anticancer C-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxic (Journal of Clinical Investigation (2013) 123:11 (4980) DOI:10.1172/JCI73378)

Ariel Fernández, Angela Sanguino, Zhenghong Peng, Eylem Ozturk, Jianping Chen, Alejandro Crespo, Sarah Wulf, Aleksander Shavrin, Chaoping Qin, Jianpeng Ma, Jonathan Trent, Yvonne Lin, Hee Dong Han, Lingegowda S. Mangala, James A. Bankson, Juri Gelovani, Allen Samarel, William Bornmann, Anil K. Sood, Gabriel Lopez-Berestein

Research output: Contribution to journalComment/debate

Original languageEnglish (US)
Number of pages1
JournalJournal of Clinical Investigation
Volume123
Issue number11
DOIs
StatePublished - Nov 1 2013

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Fernández, A., Sanguino, A., Peng, Z., Ozturk, E., Chen, J., Crespo, A., Wulf, S., Shavrin, A., Qin, C., Ma, J., Trent, J., Lin, Y., Han, H. D., Mangala, L. S., Bankson, J. A., Gelovani, J., Samarel, A., Bornmann, W., Sood, A. K., & Lopez-Berestein, G. (2013). Erratum: An anticancer C-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxic (Journal of Clinical Investigation (2013) 123:11 (4980) DOI:10.1172/JCI73378). Journal of Clinical Investigation, 123(11). https://doi.org/10.1172/JCI32373